1 A total of
1009 patients were included in the original trials, of which 995 h
2 106 patients were included in this analysis, 34 receiving apheres
3 One hundred and eighteen eyes of
118 patients were included in the study.
4 ere used to optimize the imaging protocol; the remaining
12 patients were included in the analysis dataset.
5 otal of 26 studies (including the local database) with
1209 patients were included in this meta-analysis.
6 Overall,
160 patients were included in this study.
7 , 49 publications comprising 128 test evaluations in 15
199 patients were included in the analysis.
8 Results Overall, 1,
208 patients were included in the meta-analysis (605 patients in
9 Results Ten articles with a total of
214 patients were included in the analysis.
10 A total of
219 patients were included in the unmatched cohort (143 moderate
11 A total of 2456 eyes of
2367 patients were included in the study.
12 complete any PRO instruments at any timepoints, and so
299 patients were included in the full analysis set.
13 A total of
311 patients were included in the study, with a mean (SD) age of
14 A total of
316 patients were included in the analysis (mean [SD] age, 70.3 [
15 In all,
3184 patients were included in these analyses.
16 A total of
3302 patients were included in the study, with a median age of 50
17 A total of
3365 patients were included in the intention-to-treat analyses (me
18 A total of
353 patients were included in the study.
19 All
39 patients were included in the safety analyses.
20 4358 patients were included in the per-protocol analysis, and no d
21 A total of 4 randomized clinical trials were pooled;
4394 patients were included in the analysis.
22 Fifty-three studies and
45900 patients were included in the meta-analysis.
23 pplying appropriate inclusion and exclusion criteria,
56477 patients were included in our analysis.
24 A total of
61 patients were included in the study.
25 A total of
7386 patients were included in the analysis; of these, 4236 (57.4%
26 A total of
775 patients were included in the study.
27 808 patients were included in the safety population, 726 were inc
28 ed the modified intention-to-treat population and 109 (
87%)
patients were included in the per-protocol primary efficacy a
29 ing patients with prior coronary artery bypass surgery,
925 patients were included in the analysis.
30 70
930 patients were included in the analysis, of whom 67 644 receiv
31 Hershey Medical Center,
95 patients were included in this systematic review.
32 re excluded after central pathology review; hence, 71 (
95%)
patients were included in the analysis.
33 A total of 19,
998 patients were included in the main analysis: 31 observational
34 All randomly
assigned patients were included in the primary efficacy analysis.
35 All randomly
assigned patients were included in the safety analysis.
36 174 relapsing-remitting MS/
CIS patients were included in this analysis (mean age of 15.0 yea
37 Ultimately, 1783
consecutive patients were included in the study.
38 Eleven patients were included in this study.
39 All
enrolled patients were included in primary analyses, with the exceptio
40 Forty-
five patients were included in the series, 19 with smooth-bordered
41 Results Seven hundred seventy-
five patients were included in the study (the median age at diagno
42 Two hundred fifty-
four patients were included in the mapping of the data with almost
43 Twenty-
one patients were included in this prospective scan-rescan study.
44 All
randomised patients were included in the time to clinically meaningful d
45 patients, 5928 endovascular and 5928 open
revascularization patients were included in matched analysis.
46 Four hundred
seventy patients were included in the present analysis.
47 Twenty-
six patients were included in the following groups: (i) untreated
48 could be verified histologically or MP radiologically,
the patients were included in this descriptive retro perspective
49 Ninety-
two patients were included in the analysis (48.5 [37-56] years ol
50 One hundred ninety-
two patients were included in the study cohort; median patient ag